’ (1) Loeffler, G.; Petrides, P. E. Biochemie and Pathobiochemie, 7th ed.; Springer: Berlin, Heidelberg, New York, 2003. (2) Samuelsson, B.; Morgenstern, R.; Jakobsson, P. J. Membrane
prostaglandin E synthase-1: a novel therapeutic target. Pharmacol. Rev. 2007, 59, 207–224. (3) Mehrotra, S.; Morimiya, A.; Agarwal, B.; Konger, R.; Badve, S.
Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. J. Pathol. 2006, 208, 356–363. (4) Friesen, R. W.; Mancini, J. A. Microsomal prostaglandin E2
synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target. J. Med. Chem. 2008, 51, 4059–4067. (5) Thoren, S.; Jakobsson, P. J. Coordinate up- and down-regulation
of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4. Eur. J. Biochem. 2000, 267, 6428–6434. (6) Quraishi, O.; Mancini, J. A.; Riendeau, D. Inhibition of inducible
prostaglandin E(2) synthase by 15-deoxy-delta(12,14)-prostaglandin J(2) and polyunsaturated fatty acids. Biochem. Pharmacol. 2002, 63,
1183–1189. (7) Riendeau, D.; Aspiotis, R.; Ethier, D.; Gareau, Y.; Grimm, E. L.;
Guay, J.; Guiral, S.; Juteau, H.; Mancini, J. A.; Methot, N.; Rubin, J.; Friesen, R. W. Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg. Med. Chem. Lett. 2005, 15, 3352–3355. (8) AbdulHameed, M. D.; Hamza, A.; Liu, J.; Huang, X.; Zhan, C. G.
Human microsomal prostaglandin E synthase-1 (mPGES-1) binding with inhibitors and the quantitative structureÀactivity correlation. J. Chem. Inf. Model. 2008, 48, 179–185. (9) Cote, B.; Boulet, L.; Brideau, C.; Claveau, D.; Ethier, D.;
Frenette, R.; Gagnon, M.; Giroux, A.; Guay, J.; Guiral, S.; Mancini, J.;
Martins, E.; Masse, F.; Methot, N.; Riendeau, D.; Rubin, J.; Xu, D.; Yu, H.; Ducharme, Y.; Friesen, R. W. Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg. Med.
Chem. Lett. 2007, 17, 6816–6820. (10) Claveau, D.; Sirinyan, M.; Guay, J.; Gordon, R.; Chan, C. C.;
Bureau, Y.; Riendeau, D.; Mancini, J. A. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J. Immunol. 2003, 170,
4738–4744.
(11) San Juan, A. A.; Cho, S. J. 3D-QSAR study of microsomal prostaglandin E2 synthase (mPGES-1) inhibitors. J. Mol. Model. 2007,
13, 601–610.
(12) Jakobsson, P. J.; Morgenstern, R.; Mancini, J.; Ford-Hutchinson,
A.; Persson, B. Common structural features of MAPEG—a widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism. Protein Sci. 1999, 8, 689–692.
(13) Jegerschold, C.; Pawelzik, S. C.; Purhonen, P.; Bhakat, P.;
Gheorghe, K. R.; Gyobu, N.; Mitsuoka, K.; Morgenstern, R.; Jakobsson,
P. J.; Hebert, H. Structural basis for induced formation of the inflammatory mediator prostaglandin E2. Proc. Natl. Acad. Sci. U.S.A. 2008,
105, 11110–11115.
(14) Rorsch, F.; Wobst, I.; Zettl, H.; Schubert-Zsilavecz, M.; Grosch,
S.; Geisslinger, G.; Schneider, G.; Proschak, E. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol. J. Med. Chem. 2010, 53, 911–915.
(15) Koeberle, A.; Zettl, H.; Greiner, C.; Wurglics, M.; Schubert-
Zsilavecz, M.; Werz, O. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J. Med. Chem. 2008, 51, 8068–8076.
(16) Hessler, G.; Baringhaus, K.-H. The scaffold hopping potential of pharmacophores. Drug Discovery Today: Technol. 2010, 7, 263–269.
(17) K oberle, A.; Zettl, H.; Greiner, C.; Wurglics, M.; Schubert-